Sarcoma
Sarcoma: Invited Discussant 1479PD, 1480PD, 1481PD and 1482PD
Date
11 Sep 2017Session
SarcomaPresenters
Robert MakiAuthors
R. MakiAuthor affiliations
- Medical Oncology, North Shore-LIJ Health System, 11040 - New Hyde Park/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
1811 - Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib
Presenter: Yukinori Kurokawa
Session: Sarcoma
Resources:
Abstract
4238 - A Phase 2 Study of CMB305 and Atezolizumab in NY-ESO-1+ Soft Tissue Sarcoma: Interim Analysis of Immunogenicity, Tumor Control and Survival
Presenter: Sant Chawla
Session: Sarcoma
Resources:
Abstract
5361 - Efficacy and Safety of Palbociclib in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib
Presenter: Antoine Italiano
Session: Sarcoma
Resources:
Abstract
1605 - Notch pathway inhibition with LY3039478 in soft tissue sarcoma (STS) and gastrointestinal stromal tumours (GIST)
Presenter: Olivier Mir
Session: Sarcoma
Resources:
Abstract
4513 - Imatinib in combination with everolimus in patients with progressive advanced chordoma: results form an Italian phase 2 clinical trial.
Presenter: Silvia Stacchiotti
Session: Sarcoma
Resources:
Abstract
2080 - A Matching-Adjusted Indirect Comparison of Trabectedin and Pazopanib for the Treatment of Advanced, Metastatic, Leiomyosarcomas
Presenter: Robin Jones
Session: Sarcoma
Resources:
Abstract
Sarcoma: Invited Discussant 1483PD, 1484PD and LBA57
Presenter: Mikael Eriksson
Session: Sarcoma
Resources:
Slides
Webcast
Sarcoma: Invited Discussant 1475PD, 1476PD, 1477PD and 1478PD
Presenter: Sylvie Bonvalot
Session: Sarcoma
Resources:
Slides
Webcast
4090 - Results of the LMS03 phase II study evaluating gemcitabine combined with pazopanib as a 2nd-line treatment for metastatic/relapsed leiomyosarcomas (uterine or soft tissue) after failure of anthracycline-based chemotherapy: the UNICANCER SARCOME 11 study.
Presenter: Patricia Pautier
Session: Sarcoma
Resources:
Abstract